clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Chlamydial Pneumonia D061387 2 associated lipids
Sacroiliitis D058566 1 associated lipids
Plaque, Atherosclerotic D058226 7 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Upper Extremity Deep Vein Thrombosis D056824 1 associated lipids
Leprosy, Paucibacillary D056005 2 associated lipids
Extensively Drug-Resistant Tuberculosis D054908 1 associated lipids
Buruli Ulcer D054312 1 associated lipids
Immune Reconstitution Inflammatory Syndrome D054019 1 associated lipids
Renal Insufficiency D051437 8 associated lipids
Desulfovibrionaceae Infections D045824 5 associated lipids
Chlamydophila Infections D023521 4 associated lipids
Epilepsy, Partial, Motor D020938 1 associated lipids
Central Nervous System Protozoal Infections D020808 3 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
alpha 1-Antitrypsin Deficiency D019896 3 associated lipids
Tooth, Nonvital D019553 2 associated lipids
Gingival Overgrowth D019214 7 associated lipids
Carcinoma, Lewis Lung D018827 22 associated lipids
Cryptogenic Organizing Pneumonia D018549 3 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Soft Tissue Infections D018461 2 associated lipids
Pneumonia, Bacterial D018410 16 associated lipids
Cardiovascular Abnormalities D018376 2 associated lipids
Tuberculosis, Multidrug-Resistant D018088 6 associated lipids
Cytomegalovirus Retinitis D017726 2 associated lipids
Community-Acquired Infections D017714 8 associated lipids
Soft Tissue Injuries D017695 2 associated lipids
Periodontal Attachment Loss D017622 7 associated lipids
Kleine-Levin Syndrome D017593 1 associated lipids
Cutaneous Fistula D017577 1 associated lipids
Pityriasis Rosea D017515 3 associated lipids
Dermatitis, Phototoxic D017484 4 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
Liver Failure, Acute D017114 11 associated lipids
IgA Deficiency D017098 2 associated lipids
AIDS-Related Opportunistic Infections D017088 9 associated lipids
Common Variable Immunodeficiency D017074 4 associated lipids
Meningitis, Bacterial D016920 6 associated lipids
Angiomatosis, Bacillary D016917 2 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Ureaplasma Infections D016869 5 associated lipids
Empyema, Pleural D016724 2 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
Purpura, Thrombocytopenic, Idiopathic D016553 4 associated lipids
Bronchial Hyperreactivity D016535 15 associated lipids
Helicobacter Infections D016481 21 associated lipids
Bacteremia D016470 9 associated lipids
Prosthesis-Related Infections D016459 7 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Eye Infections, Bacterial D015818 3 associated lipids
Eye Infections D015817 1 associated lipids
Eye Injuries, Penetrating D015807 2 associated lipids
Leprosy, Lepromatous D015440 2 associated lipids
Leprosy, Borderline D015439 3 associated lipids
Discitis D015299 2 associated lipids
Mycobacterium avium-intracellulare Infection D015270 4 associated lipids
Sexually Transmitted Diseases, Bacterial D015231 5 associated lipids
Wound Infection D014946 12 associated lipids
Whooping Cough D014917 6 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Urticaria D014581 13 associated lipids
Urination Disorders D014555 9 associated lipids
Urinary Tract Infections D014552 11 associated lipids
Urethritis D014526 9 associated lipids
Ureteral Obstruction D014517 10 associated lipids
Ureteral Diseases D014515 3 associated lipids
Typhoid Fever D014435 2 associated lipids
Tuberculosis, Spinal D014399 1 associated lipids
Tuberculosis, Pulmonary D014397 18 associated lipids
Tuberculosis, Ocular D014392 1 associated lipids
Tuberculosis, Avian D014379 2 associated lipids
Tuberculosis D014376 20 associated lipids
Tooth Discoloration D014075 7 associated lipids
Tenosynovitis D013717 3 associated lipids
Syphilis D013587 6 associated lipids
Synovitis D013585 15 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Stomach Ulcer D013276 75 associated lipids
Stomach Neoplasms D013274 24 associated lipids
Stomach Diseases D013272 7 associated lipids
Sporotrichosis D013174 3 associated lipids
Splenic Diseases D013158 5 associated lipids
Skin Ulcer D012883 6 associated lipids
Skin Neoplasms D012878 12 associated lipids
Skin Diseases, Infectious D012874 7 associated lipids
Sinusitis D012852 9 associated lipids
Shock, Septic D012772 11 associated lipids
Serositis D012700 1 associated lipids
Scrub Typhus D012612 3 associated lipids
Rosacea D012393 13 associated lipids
Rodent Diseases D012376 4 associated lipids
Rickettsia Infections D012282 5 associated lipids
Rhabdomyolysis D012206 9 associated lipids
Radiation Injuries D011832 14 associated lipids
Pyelonephritis D011704 5 associated lipids
Psychoses, Substance-Induced D011605 7 associated lipids
Psychophysiologic Disorders D011602 3 associated lipids
Psoriasis D011565 47 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Lara-Martín PA et al. Occurrence, distribution and partitioning of nonionic surfactants and pharmaceuticals in the urbanized Long Island Sound Estuary (NY). 2014 Mar. Pollut. Bull. pmid:24467856
Saadat A et al. The formulation, chemical and physical characterisation of clarithromycin-based macrolide solution pressurised metered dose inhaler. 2014 J. Pharm. Pharmacol. pmid:24329164
Rajput P et al. Bifunctional capsular dosage form: novel fanicular cylindrical gastroretentive system of clarithromycin and immediate release granules of ranitidine HCl for simultaneous delivery. 2014 Int J Pharm pmid:24309435
Furuta T et al. Effect of dosing schemes of amoxicillin on eradication rates of Helicobacter pylori with amoxicillin-based triple therapy. 2014 J Clin Pharmacol pmid:24122836
Ratzinger F et al. Azithromycin suppresses CD4(+) T-cell activation by direct modulation of mTOR activity. 2014 Sci Rep pmid:25500904
Trotti LM et al. Improvement in daytime sleepiness with clarithromycin in patients with GABA-related hypersomnia: Clinical experience. 2014 J. Psychopharmacol. (Oxford) pmid:24306133
Nie W et al. [The analysis of species identification and susceptibility testing of Mycobacterium abscessus]. 2014 Zhonghua Jie He He Hu Xi Za Zhi pmid:25262693
Iwanaga K and Carter ER Mycobacterium abscessus complex lung infection in a toddler with a tracheostomy. 2014 Pediatr. Pulmonol. pmid:23460506
Campanale M et al. Nickel free-diet enhances the Helicobacter pylori eradication rate: a pilot study. 2014 Dig. Dis. Sci. pmid:24595654
Schuhfried G et al. Gilles de la Tourette Syndrome caused by Mycoplasma pneumoniae successfully treated with macrolides. 2014 Klin Padiatr pmid:25153913
Svanström H et al. Use of clarithromycin and roxithromycin and risk of cardiac death: cohort study. 2014 BMJ pmid:25139799
Giamarellos-Bourboulis EJ et al. Effect of clarithromycin in patients with suspected Gram-negative sepsis: results of a randomized controlled trial. 2014 J. Antimicrob. Chemother. pmid:24292991
Zhao Y and Hu ZY Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate. 2014 Br. J. Pharmacol. pmid:24283665
Harvey E and Varatharaj A Round pneumonia. 2014 QJM pmid:23708793
Oztürk K et al. Diagnosis of helicobacter pylori infection. 2014 Turk J Gastroenterol pmid:25141328
Lee JY and Kim N [Future trends of Helicobacter pylori eradication therapy in Korea]. 2014 Korean J Gastroenterol pmid:24651589
Lee SH et al. The drug resistance profile of Mycobacterium abscessus group strains from Korea. 2014 Ann Lab Med pmid:24422193
Pathak V et al. Macrolide use leads to clinical and radiological improvement in patients with cryptogenic organizing pneumonia. 2014 Ann Am Thorac Soc pmid:24460438
Wu JY et al. Evidence-based recommendations for successful Helicobacter pylori treatment. 2014 Expert Rev Gastroenterol Hepatol pmid:24410470
Sugamata R et al. Leucomycin A3, a 16-membered macrolide antibiotic, inhibits influenza A virus infection and disease progression. 2014 J. Antibiot. pmid:24496145
Díaz Cuevas Z et al. [Nodular skin lesions in a patient with rheumatoid arthritis under therapy with anti-tumor necrosis factor-α]. 2014 Med Clin (Barc) pmid:23877097
Jung YS et al. [Trends in the eradication rates of Helicobacter pylori infection in Daegu and Gyeongsangbuk-do, Korea: multicenter study over 13 years]. 2014 Korean J Gastroenterol pmid:24561694
Vanderpas J et al. Follow-up of Helicobacter pylori infection in children over two decades (1988-2007): persistence, relapse and acquisition rates. 2014 Epidemiol. Infect. pmid:23809783
Oğuz M and Mihçiokur H Environmental risk assessment of selected pharmaceuticals in Turkey. 2014 Environ. Toxicol. Pharmacol. pmid:24929476
Maurer FP et al. Erm(41)-dependent inducible resistance to azithromycin and clarithromycin in clinical isolates of Mycobacterium abscessus. 2014 J. Antimicrob. Chemother. pmid:24500188
Tranos P et al. Bilateral diffuse iris atrophy after the use of oral clarithromycin. 2014 Cutan Ocul Toxicol pmid:23763291
Bouricha M et al. Mycobacterium marinum infection following contact with reptiles: vivarium granuloma. 2014 Int. J. Infect. Dis. pmid:24530276
Peedikayil MC et al. Levofloxacin-based first-line therapy versus standard first-line therapy for Helicobacter pylori eradication: meta-analysis of randomized controlled trials. 2014 PLoS ONE pmid:24465624
Yoshida N et al. A cross-sectional investigation of the quality of selected medicines in Cambodia in 2010. 2014 BMC Pharmacol Toxicol pmid:24593851
Vu DH et al. Simultaneous determination of rifampicin, clarithromycin and their metabolites in dried blood spots using LC-MS/MS. 2014 Talanta pmid:24607103
Zaiem A et al. Clarithromycin induced psoriasis in a 37-year old man. 2014 Curr Drug Saf pmid:24410388
de Masson A et al. Cavitary pulmonary disease in a patient treated with natalizumab. 2014 Presse Med pmid:24742610
Furuta T et al. Sitafloxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan. 2014 J. Gastroenterol. Hepatol. pmid:24224808
Noguchi S et al. Polymorphic transformation of antibiotic clarithromycin under acidic condition. 2014 J Pharm Sci pmid:24375227
Phillips RO et al. Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease. 2014 Antimicrob. Agents Chemother. pmid:24323473
McNicholl AG et al. Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. 2014 Gut pmid:23665990
Srinarong C et al. Improved eradication rate of standard triple therapy by adding bismuth and probiotic supplement for Helicobacter pylori treatment in Thailand. 2014 Asian Pac. J. Cancer Prev. pmid:25520127
Komiya K et al. Long-term, low-dose erythromycin monotherapy for Mycobacterium avium complex lung disease: a propensity score analysis. 2014 Int. J. Antimicrob. Agents pmid:24948577
Homma S et al. The successful management of respiratory complications with long-term, low-dose macrolide administration in pediatric heart transplant recipients. 2014 Int Heart J pmid:25297501
Renvoisé A et al. Significant difference in drug susceptibility distribution between Mycobacterium avium and Mycobacterium intracellulare. 2014 J. Clin. Microbiol. pmid:25274991
Tu S and Yang H [Progress in the treatment of Helicobacter pylori infection]. 2014 Zhong Nan Da Xue Xue Bao Yi Xue Ban pmid:25269503
Malfertheiner P and Selgrad M Helicobacter pylori. 2014 Curr. Opin. Gastroenterol. pmid:25268839
Ito Y et al. The influence of environmental exposure on the response to antimicrobial treatment in pulmonary Mycobacterial avium complex disease. 2014 BMC Infect. Dis. pmid:25266993
de Miguel-Martinez I et al. [Bacteriemia due to Mycobacterium canariasense in an oncohematological patient with a long-term central device]. 2014 Enferm. Infecc. Microbiol. Clin. pmid:25262854
Gui J et al. [Subspecies identification for Mycobacterium abscessus group]. 2014 Zhonghua Jie He He Hu Xi Za Zhi pmid:25262692
Ghrew MH et al. Successful renal transplant in patient with controlled pulmonary non-tuberculous mycobacterium infection. 2014 Libyan J Med pmid:25249307
Yoon KH et al. Clarithromycin-based standard triple therapy can still be effective for Helicobacter pylori eradication in some parts of the Korea. 2014 J. Korean Med. Sci. pmid:25246742
Higgins JW et al. Clinical CYP3A inhibitor alternatives to ketoconazole, clarithromycin and itraconazole, are not transported into the liver by hepatic organic anion transporting polypeptides and organic cation transporter 1. 2014 Drug Metab. Dispos. pmid:25106415
Boleda MR et al. Survey of the occurrence of pharmaceuticals in Spanish finished drinking waters. 2014 Environ Sci Pollut Res Int pmid:24756682
Nilsson MF and Webster WS Effects of macrolide antibiotics on rat embryonic heart function in vitro. 2014 Birth Defects Res. B Dev. Reprod. Toxicol. pmid:24753334
Peng YC et al. Clarithromycin modulates Helicobacter pylori-induced activation of nuclear factor-κB through classical and alternative pathways in gastric epithelial cells. 2014 Clin. Exp. Med. pmid:23129507
Wallace RJ et al. Macrolide/Azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease. 2014 Chest pmid:24457542
Molina-Infante J and Gisbert JP Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance. 2014 World J. Gastroenterol. pmid:25132750
Heo J et al. A randomised clinical trial of 10-day concomitant therapy and standard triple therapy for Helicobacter pylori eradication. 2014 Dig Liver Dis pmid:25132282
Lebedeva MV et al. Clarithromycin as a chiral selector for enantioseparation of basic compounds in nonaqueous capillary electrophoresis. 2014 Electrophoresis pmid:25100556
Katayama M et al. Preliminary study of interaction of clarithromycin with tacrolimus in cats. 2014 J. Vet. Med. Sci. pmid:25099737
Park CS et al. Pretreatment antimicrobial susceptibility-guided vs. clarithromycin-based triple therapy for Helicobacter pylori eradication in a region with high rates of multiple drug resistance. 2014 Am. J. Gastroenterol. pmid:25091062
Cicek-Senturk G et al. Acute mercury poisoning presenting as fever of unknown origin in an adult woman: a case report. 2014 J Med Case Rep pmid:25084829
Bilgin M et al. Acute coronary syndrome secondary to clarithromycin: the first case and review of the literature. 2014 Turk Kardiyol Dern Ars pmid:25080953
Rakici H et al. Comparison of standard triple therapy, sequential therapy and moxifloxacin-based triple therapy for Helicobacter pylori infection: Patients' compliance and bacterial eradication rates. 2014 J Dig Dis pmid:24980811
Acosta CP et al. [Determination of single nucleotide mutations in the 23S rRNA gene of Helicobacter pylori related to clarithromycin resistance in a population from Cauca, Colombia]. 2014 Biomedica pmid:24968047
Lee JW et al. GenoType HelicoDR test in the determination of antimicrobial resistance of Helicobacter pylori in Korea. 2014 Scand. J. Gastroenterol. pmid:24957849
Raffaldi I et al. An atypical deep neck infection in a two-year-old child. 2014 Infez Med pmid:24955801
Oh DH et al. Efficacy of hybrid therapy as first-line regimen for Helicobacter pylori infection compared with sequential therapy. 2014 J. Gastroenterol. Hepatol. pmid:24955448
Patel K et al. Oral delivery of paclitaxel nanocrystal (PNC) with a dual Pgp-CYP3A4 inhibitor: preparation, characterization and antitumor activity. 2014 Int J Pharm pmid:24954663
Vafaeimanesh J et al. Expression comparison of azithromycin and clarithromycin in triple-therapy regimens for eradication of Helicobacter pylori in hemodialysis patients. 2014 Saudi J Kidney Dis Transpl pmid:24434382
Bonferoni MC et al. Ionic polymeric micelles based on chitosan and fatty acids and intended for wound healing. Comparison of linoleic and oleic acid. 2014 Eur J Pharm Biopharm pmid:24384070
Liu CP et al. NO-releasing xanthine KMUP-1 bonded by simvastatin attenuates bleomycin-induced lung inflammation and delayed fibrosis. 2014 Pulm Pharmacol Ther pmid:23518214
Philips RC et al. Mycobacterium fortuitum infection arising in a new tattoo. 2014 Dermatol. Online J. pmid:24945647
Klesiewicz K et al. PCR-RFLP detection of point mutations A2143G and A2142G in 23S rRNA gene conferring resistance to clarithromycin in Helicobacter pylori strains. 2014 Acta Biochim. Pol. pmid:24927236
Jarand J and Field SK Embrace simplicity when treating lady windermere. 2014 Chest pmid:25091749
Bolhuis MS et al. In vitro synergy between linezolid and clarithromycin against Mycobacterium tuberculosis. 2014 Eur. Respir. J. pmid:24791826
Zhao LJ et al. Helicobacter pylori isolates from ethnic minority patients in Guangxi: resistance rates, mechanisms, and genotype. 2014 World J. Gastroenterol. pmid:24782630
Peretz A et al. Resistance of Helicobacter pylori to tetracycline, amoxicillin, clarithromycin and metronidazole in Israeli children and adults. 2014 J. Antibiot. pmid:24781955
Nishida T et al. Comparative study of esomeprazole and lansoprazole in triple therapy for eradication of Helicobacter pylori in Japan. 2014 World J. Gastroenterol. pmid:24764674
Zhou L et al. Relationship of Helicobacter pylori eradication with gastric cancer and gastric mucosal histological changes: a 10-year follow-up study. 2014 Chin. Med. J. pmid:24762588
Luo Q et al. [Clinical effect of clarithromycin therapy in patients with chronic rhinosinusitis]. 2014 Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi pmid:24742507
Trotti LM et al. Further experience using clarithromycin in patients with Kleine-Levin syndrome. 2014 J Clin Sleep Med pmid:24733995
Khalili N Sunny hypomania associated with clarithromycin: a case report. 2014 J Clin Psychopharmacol pmid:24717249
Onyekwere CA et al. Rabeprazole, clarithromycin, and amoxicillin Helicobacter pylori eradication therapy: report of an efficacy study. 2014 World J. Gastroenterol. pmid:24707145
Wu JY et al. Detection of genotypic clarithromycin-resistant Helicobacter pylori by string tests. 2014 World J. Gastroenterol. pmid:24695835
Sugimoto M et al. Efficacy of tailored Helicobacter pylori eradication treatment based on clarithromycin susceptibility and maintenance of acid secretion. 2014 Helicobacter pmid:24690010
Liu KY et al. Efficacy and pharmacological mechanism of pronase-enhanced low-dose antibiotics for Helicobacter pylori eradication. 2014 Antimicrob. Agents Chemother. pmid:24687504
Karaolia P et al. Reduction of clarithromycin and sulfamethoxazole-resistant Enterococcus by pilot-scale solar-driven Fenton oxidation. 2014 Sci. Total Environ. pmid:24012892
Ali Habib HS et al. Effect of sequential versus standard Helicobacter pylori eradication therapy on the associated iron deficiency anemia in children. 2013 Sep-Oct Indian J Pharmacol pmid:24130381
Mégraud F Current recommendations for Helicobacter pylori therapies in a world of evolving resistance. 2013 Nov-Dec Gut Microbes pmid:23929066
Suzaki I et al. Enhancement of thioredoxin production from nasal epithelial cells by the macrolide antibiotic, clarithromycin in vitro. 2013 May-Jun In Vivo pmid:23606690
Dajani AI et al. Do probiotics improve eradication response to Helicobacter pylori on standard triple or sequential therapy? 2013 May-Jun Saudi J Gastroenterol pmid:23680708
Petitto J et al. Successful clarithromycin desensitization in a macrolide-sensitive pediatric patient. 2013 May-Jun J Allergy Clin Immunol Pract pmid:24565493
Cottle LE et al. A multinational outbreak of histoplasmosis following a biology field trip in the Ugandan rainforest. 2013 Mar-Apr J Travel Med pmid:23464714
Molina-Infante J and Gisbert JP [Update on the efficacy of triple therapy for Helicobacter pylori infection and clarithromycin resistance rates in Spain (2007-2012)]. 2013 Jun-Jul Gastroenterol Hepatol pmid:23623461
Razafimahefa SH et al. [Helicobacter pylori: what eradication regimen in a tropical area after the failure of two separate lines of eradication including metronidazole and clarithromycin?]. 2013 Jan-Mar Med Sante Trop pmid:23360589
Mandras N et al. Antibacterial efficacy and drug-induced tooth discolouration of antibiotic combinations for endodontic regenerative procedures. 2013 Apr-Jun Int J Immunopathol Pharmacol pmid:23755774
Herath SC and Poole P Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD). 2013 Cochrane Database Syst Rev pmid:24288145
Piso RJ et al. Coverage of atypical pathogens for hospitalised patients with community-acquired pneumonia is not guided by clinical parameters. 2013 Swiss Med Wkly pmid:24089030
Tsukanov VV et al. [Helicobacter pylori eradication: current status]. 2013 Ter. Arkh. pmid:23653944
Radouane N et al. [Generalized chromomycosis caused by Phialophora verrucosa]. 2013 Ann Dermatol Venereol pmid:23466152
Dabirmoghaddam P et al. The efficacy of clarithromycin in patients with severe nasal polyposis. 2013 Acta Med Iran pmid:23852839
Lin KJ et al. Safety of macrolides during pregnancy. 2013 Am. J. Obstet. Gynecol. pmid:23254249
Bolhuis MS et al. Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients. 2013 Eur. Respir. J. pmid:23520311